Document Classification

Section Type: RESULTS

Text: At the 24-month follow-up visit, mean change in composite scores with ranibizumab seemed to be better than control for both better-seeing eyes (8. 4 [95 % confidence interval (CI), 5. 2-11. 6], 7. 5 [95 % CI, 3. 7-11. 4], and -9. 4 [95 % CI, -12. 5 to -6. 3] for the 0. 3-mg, 0. 5-mg, and sham groups, respectively) and worse-seeing eyes (1. 7 [95 % CI, -1. 1 to 4. 4], 1. 7 [95 % CI, -0. 7 to 4. 1], and -5. 4 [95 % CI, -7. 9 to -2. 8] for the 0. 3-mg, 0. 5-mg, and sham groups, respectively) in MARINA, as well as the better-seeing eye in ANCHOR (11. 3 [95 % CI, 5. 3-17. 3], 13. 3 [95 % CI, 7. 7-19. 0], and -2. 7 [95 % CI, -9. 0 to 3. 7] for the 0. 3-mg, 0. 5-mg, and PDT groups, respectively).